Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells

被引:76
作者
Zhuo, Wei [1 ,2 ,3 ]
Luo, Chong [1 ,2 ,3 ]
Wang, Xiaofeng [1 ,2 ,3 ]
Song, Xiaomin [1 ,2 ,3 ]
Fu, Yan [1 ,2 ,3 ]
Luo, Yongzhang [1 ,2 ,3 ]
机构
[1] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China
[2] Tsinghua Univ, Beijing Key Lab Prot Therapeut, Canc Biol Lab, Beijing 100084, Peoples R China
[3] Tsinghua Univ, Natl Engn Lab Antitumour Prot Therapeut, Beijing 100084, Peoples R China
基金
国家高技术研究发展计划(863计划); 中国国家自然科学基金;
关键词
endostatin; nucleolin; lymphangiogenesis; endothelial cell; lymph node; tumour metastasis; GROWTH-FACTOR-C; NODE METASTASIS; INTRATUMORAL LYMPHANGIOGENESIS; ENDOGENOUS INHIBITOR; AIRWAY INFLAMMATION; ANTITUMOR-ACTIVITY; BREAST-CANCER; VEGF-C; ANGIOGENESIS; HYPERPLASIA;
D O I
10.1002/path.2760
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Endostatin has potent anti-endothelial and anti-angiogenic functions. Endostatin was reported to reduce lymphangiogenesis by down-regulating the level of VEGF-C in tumour tissues. However, there is little evidence for the direct function of endostatin on lymphangiogenic endothelial cells and lymphangiogenic vessels. Here, we report that cell surface nucleolin, which was reported as an endostatin receptor mediating its anti-angiogenic and anti-tumour functions, is also selectively expressed on the cell surface of lymphangiogenic endothelial cells both in vitro and in vivo. Treatment of primary mouse lymphatic endothelial cells (mLECs) by endostatin inhibits mLEC migration, tubule formation, and activation of the Erk pathway in mLECs, while neutralization of cell surface nucleolin or nucleolin knockdown results in loss of the anti-lymphatic endothelial activities of endostatin. Also, anti-nucleolin antibody or lentivirus delivered nucleolin siRNA abolishes the anti-lymphangiogenic function of endostatin in the Matrigel plug assay. Endostatin remarkably inhibits tumour-associated lymphangiogenesis, leading to reduced lymphatic metastasis. Systemic blockade of nucleolin notably abolishes the anti-lymphangiogenic and anti-lymphatic metastatic functions of endostatin. Importantly, endostatin does not affect quiescent lymphatics in normal organs, which is consistent with the lack of expression of cell surface nucleolin in quiescent lymphatics. Taken together, our results demonstrate that endostatin directly acts on lymphangiogenic endothelial cells via cell surface nucleolin, which provides a novel mechanism for the inhibition of tumour lymphangiogenesis and lymphatic metastasis by endostatin. Copyright (C) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:249 / 260
页数:12
相关论文
共 46 条
[1]   Endostatin's antiangiogenic signaling network [J].
Abdollahi, A ;
Hahnfeldt, P ;
Maercker, C ;
Gröne, HJ ;
Debus, J ;
Ansorge, W ;
Folkman, J ;
Hlatky, L ;
Huber, PE .
MOLECULAR CELL, 2004, 13 (05) :649-663
[2]   Targeting lymphangiogenesis to prevent tumour metastasis [J].
Achen, M. G. ;
Mann, G. B. ;
Stacker, S. A. .
BRITISH JOURNAL OF CANCER, 2006, 94 (10) :1355-1360
[3]   Focus on lymphangiogenesis in tumor metastasis [J].
Achen, MG ;
McColl, BK ;
Stacker, SA .
CANCER CELL, 2005, 7 (02) :121-127
[4]   Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth [J].
Albuquerque, Romulo J. C. ;
Hayashi, Takahiko ;
Cho, Won Gil ;
Kleinman, Mark E. ;
Dridi, Sami ;
Takeda, Atsunobu ;
Baffi, Judit Z. ;
Yamada, Kiyoshi ;
Kaneko, Hiroki ;
Green, Martha G. ;
Chappell, Joe ;
Wilting, Joerg ;
Weich, Herbert A. ;
Yamagami, Satoru ;
Amano, Shiro ;
Mizuki, Nobuhisa ;
Alexander, Jonathan S. ;
Peterson, Martha L. ;
Brekken, Rolf A. ;
Hirashima, Masanori ;
Capoor, Seema ;
Usui, Tomohiko ;
Ambati, Balamurali K. ;
Ambati, Jayakrishna .
NATURE MEDICINE, 2009, 15 (09) :1023-U74
[5]   Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation [J].
Baluk, P ;
Tammela, T ;
Ator, E ;
Lyubynska, N ;
Achen, MG ;
Hicklin, DJ ;
Jeltsch, M ;
Petrova, TV ;
Pytowski, B ;
Stacker, SA ;
Ylä-Herttuala, S ;
Jackson, DG ;
Alitalo, K ;
McDonald, DM .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) :247-257
[6]  
Beasley NJP, 2002, CANCER RES, V62, P1315
[7]   Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo [J].
Björndahl, M ;
Cao, RH ;
Nissen, LJ ;
Clasper, S ;
Johnson, LA ;
Xue, Y ;
Zhou, ZJ ;
Jackson, D ;
Hansen, AJ ;
Cao, YH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (43) :15593-15598
[8]   Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].
Boehm, T ;
Folkman, J ;
Browder, T ;
OReilly, MS .
NATURE, 1997, 390 (6658) :404-407
[9]   MAJOR NUCLEOLAR PROTEINS SHUTTLE BETWEEN NUCLEUS AND CYTOPLASM [J].
BORER, RA ;
LEHNER, CF ;
EPPENBERGER, HM ;
NIGG, EA .
CELL, 1989, 56 (03) :379-390
[10]   Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice [J].
Brideau, Gaelle ;
Makinen, Markus J. ;
Elamaa, Harri ;
Tu, Hongmin ;
Nilsson, Gunnar ;
Alitalo, Kari ;
Pihlajaniemi, Taina ;
Heljasvaara, Ritva .
CANCER RESEARCH, 2007, 67 (24) :11528-11535